Juluca (Dolutegravir/Rilpivirine) Patent Expiration, LOE Window & CMS Spending

Juluca (Dolutegravir/Rilpivirine) by GSK: FDA Orange Book core substance LOE 2031-01-24 (last listed 2038-09-05), 0 AB generics, $517.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN210192 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-01-24
Last Listed Patent or Exclusivity Date2038-09-05
Orange Book Patents (*PED Extensions)6 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$517.7M
2024 Medicare Part D Spend$415.2M
2024 Medicaid Spend$102.5M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 17.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.